Kissei Pharmaceutical Co., Ltd. (KSPHF)
| Market Cap | 940.60M -13.1% |
| Revenue (ttm) | 612.60M +10.3% |
| Net Income | 86.66M +15.2% |
| EPS | 2.09 +20.9% |
| Shares Out | n/a |
| PE Ratio | 10.85 |
| Forward PE | n/a |
| Dividend | 1.03 (4.00%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 121 |
| Average Volume | 525 |
| Open | 25.77 |
| Previous Close | 26.97 |
| Day's Range | 25.77 - 25.77 |
| 52-Week Range | 23.23 - 31.90 |
| Beta | -0.15 |
| RSI | 53.90 |
| Earnings Date | May 11, 2026 |
About Kissei Pharmaceutical
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of rena... [Read more]
Financial Performance
In fiscal year 2026, Kissei Pharmaceutical's revenue was 97.41 billion, an increase of 10.28% compared to the previous year's 88.33 billion. Earnings were 13.78 billion, an increase of 15.20%.
Financial numbers in JPY Financial StatementsNews
Kissei Pharmaceutical initiated with a Neutral at UBS
UBS initiated coverage of Kissei Pharmaceutical (KSPHF) with a Neutral rating and 4,900 yen price target The firm says the company’s business stability is priced into the shares with limited…
Kissei Pharmaceutical downgraded to Hold from Buy at Jefferies
Jefferies analyst Stephen Barker downgraded Kissei Pharmaceutical to Hold from Buy with a price target of 3,400 yen, up from 3,300 yen. The analyst cites valuation for the downgrade following…